This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kalil, N. Articles by Cheson, B. D. Search for Related Content PubMed PubMed Citation Articles by Kalil, N. Articles by Cheson, B. D.

Chronic Lymphocytic Leukemia

^a Medicine Branch and Cancer Therapy Evaluation Program (CTEP); ^b Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), Executive Plaza North, Bethesda, Maryland, USA

Correspondence: Bruce D. Cheson, M.D., Head, Medicine Section, Clinical Investigation Branch, Cancer Therapy Evaluation Program, Executive Plaza North, Room 741, Bethesda, Maryland 20892, USA. Telephone 301-496-2522; Fax: 301-402-0557; e-mail: chesonb{at}ctep.nci.nih.gov

The diagnosis and management of chronic lymphocytic leukemia (CLL) is reviewed, including the basic aspects of epidemiology, molecular biology, and cytogenetics with clinical relevance. The importance of immunophenotype in the differential diagnosis of other lymphoproliferative disorders related to CLL, staging, prognostic factors, promising new drugs, and approaches is summarized.

Key Words. Chronic lymphocytic leukemia • CLL • CLL etiology • Biology • Cytogenetics • Diagnosis • Treatment • B-cell malignancies • Chronic lymphoproliferative disorders

This article has been cited by other articles:

				M. L. Sorror, M. B. Maris, B. M. Sandmaier, B. E. Storer, M. J. Stuart, U. Hegenbart, E. Agura, T. R. Chauncey, J. Leis, M. Pulsipher, et al. Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia J. Clin. Oncol., June 1, 2005; 23(16): 3819 - 3829. [Abstract] [Full Text] [PDF]

				H. T Wu Alemtuzumab (Campath-1H, Campath1) for the treatment of lymphoid malignancies: chronic lymphocytic leukemia and T-cell prolymphocytic leukemia Journal of Oncology Pharmacy Practice, December 1, 2001; 7(4): 133 - 140. [Abstract] [PDF]

				P. Chu, W. G. Wierda, and T. J. Kipps CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes Blood, June 15, 2000; 95(12): 3853 - 3858. [Abstract] [Full Text] [PDF]